Cargando…

免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习

A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) exa...

Descripción completa

Detalles Bibliográficos
Autores principales: LI, Shishi, ZHENG, Ke, XU, Yan, WANG, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600747/
https://www.ncbi.nlm.nih.gov/pubmed/37985157
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.17
_version_ 1785126051912876032
author LI, Shishi
ZHENG, Ke
XU, Yan
WANG, Mengzhao
author_facet LI, Shishi
ZHENG, Ke
XU, Yan
WANG, Mengzhao
author_sort LI, Shishi
collection PubMed
description A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) examination, immune checkpoint inhibitors related cystoureteritis and acute kidney injury were considered. The patient’s symptoms were relieved after discontinuation of Pembrolizumab combined with chemotherapy. However, the symptoms of urinary irritation worsened significantly after rechallenging Pembrolizumab combined with chemotherapy, and the symptoms was relieved after corticosteroids treatment. If patients develop urinary symptoms during immune checkpoint inhibitors treatment, immune checkpoint inhibitors related cystoureteritis should be considered for early differential diagnosis in order to implement appropriate treatment.
format Online
Article
Text
id pubmed-10600747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-106007472023-10-27 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 LI, Shishi ZHENG, Ke XU, Yan WANG, Mengzhao Zhongguo Fei Ai Za Zhi Case Report A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) examination, immune checkpoint inhibitors related cystoureteritis and acute kidney injury were considered. The patient’s symptoms were relieved after discontinuation of Pembrolizumab combined with chemotherapy. However, the symptoms of urinary irritation worsened significantly after rechallenging Pembrolizumab combined with chemotherapy, and the symptoms was relieved after corticosteroids treatment. If patients develop urinary symptoms during immune checkpoint inhibitors treatment, immune checkpoint inhibitors related cystoureteritis should be considered for early differential diagnosis in order to implement appropriate treatment. Editorial board of Chinese Journal of Lung Cancer 2023-09-20 /pmc/articles/PMC10600747/ /pubmed/37985157 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.17 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Case Report
LI, Shishi
ZHENG, Ke
XU, Yan
WANG, Mengzhao
免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
title 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
title_full 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
title_fullStr 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
title_full_unstemmed 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
title_short 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
title_sort 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600747/
https://www.ncbi.nlm.nih.gov/pubmed/37985157
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.17
work_keys_str_mv AT lishishi miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí
AT zhengke miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí
AT xuyan miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí
AT wangmengzhao miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí